FDA approves Cerapedics’ PearlMatrix as first proven bone growth accelerator for lumbar spinal fusion

On June 23, 2025, in Westminster, Colorado, Cerapedics Inc. announced it has received premarket approval (PMA) from the United States Food and Drug Administration (FDA) for PearlMatrix, its P-15 Peptide Enhanced Bone Graft. The decision makes PearlMatrix the first and only FDA-approved bone growth accelerator for use in single-level transforaminal lumbar interbody fusion (TLIF) procedures in adult patients suffering from degenerative disc disease (DDD). This announcement, published via PR Newswire, is based on the positive results of the ASPIRE pivotal Level-1 PMA IDE clinical trial, which showed PearlMatrix significantly outperforms traditional bone grafts in fusion speed and success rates.

The FDA’s approval classifies PearlMatrix as a Class III drug-device combination product, a designation reserved for technologies that demonstrate both safety and significant clinical efficacy. This regulatory clearance also makes Cerapedics the only company with two PMA-approved spinal fusion products in a market currently flooded with over 350 spinal bone graft offerings.

How Does PearlMatrix Differ From Other Spinal Bone Grafts?

PearlMatrix’s approval represents a breakthrough in spinal repair solutions. Unlike traditional bone grafts, which often rely on either autologous graft material or synthetic scaffolds with varying efficacy, PearlMatrix is engineered with a proprietary P-15 Osteogenic Cell Binding Peptide. This peptide is designed to mimic the biological conditions necessary for bone cell adhesion and new bone growth—thereby functioning not only as a scaffold but as an active biological stimulant.

According to Cerapedics, PearlMatrix is the first clinically proven bone growth accelerator for TLIF procedures. TLIF surgery is typically performed to remove a damaged spinal disc and stabilize the lumbar spine by fusing the surrounding vertebrae using a bone graft. While this method is widely used, the fusion process can take up to 12 months, especially in patients with comorbidities like obesity or diabetes. PearlMatrix aims to reduce this recovery timeline significantly by enhancing the speed of fusion, even among high-risk patients.

What Did the ASPIRE Trial Demonstrate About PearlMatrix Efficacy?

The FDA’s decision is based on findings from the ASPIRE trial—a prospective, single-blinded, multi-center randomized controlled study conducted across 33 medical centers in the United States. A total of 293 patients participated in the trial, approximately 60% of whom were considered high risk for non-union due to underlying conditions such as Type 2 diabetes, body mass index (BMI) ≥30, or habitual nicotine use.

The study compared PearlMatrix against local autologous bone graft and cancellous allograft in single-level TLIF surgeries. It met its primary endpoint of 24-month Composite Clinical Success (CCS), a metric that combines five criteria: radiographic fusion, improvement in Oswestry Disability Index (ODI), neurological status, absence of serious device-related adverse events, and no index-level secondary surgical interventions.

Results showed that patients treated with PearlMatrix experienced significantly faster spinal fusion compared to those treated with local autograft. Specifically, more than twice as many patients had achieved complete fusion within six months in the PearlMatrix group—a finding that substantiates its classification as a bone growth accelerator.

Dr. Michael Steinmetz, Chairman of the Department of Neurosurgery at the Cleveland Clinic and principal investigator in the ASPIRE study, stated that the trial’s high-risk patient inclusion makes the results more applicable to everyday surgical practice. He noted that most similar studies often exclude patients with comorbidities, yet the ASPIRE trial intentionally reflected real-world scenarios.

Why Is the FDA’s PMA Classification Significant for PearlMatrix?

Premarket approval (PMA) by the FDA is the most stringent level of device approval and requires manufacturers to submit scientific evidence demonstrating that a device is safe and effective for its intended use. PearlMatrix received this approval after being designated a Breakthrough Device in April 2021, which allowed Cerapedics to expedite its application process.

This approval elevates PearlMatrix’s regulatory and commercial standing. Out of more than 350 spinal bone graft products currently available in the U.S. market, only three have received PMA status—two of which now belong to Cerapedics. According to CEO Valeska Schroeder, this milestone reflects the company’s commitment to clinical rigor and its intent to provide transformative solutions in spinal surgery.

What Are the Implications for Spine Surgeons and High-Risk Patients?

With this approval, surgeons treating patients with degenerative disc disease now have access to a graft material that not only meets safety standards but is also proven to reduce recovery time and improve outcomes. This development is especially important for high-risk patient groups who are more prone to complications and longer healing periods following spinal fusion surgery.

Cerapedics emphasized that PearlMatrix can offer a practical solution for these patient populations by enhancing the biological environment required for fusion. Surgeons, particularly those working in high-volume spine centers, may now be more inclined to adopt this bone graft as a standard part of their procedural toolkit.

Dr. Steinmetz added that the ASPIRE study’s results were both clinically and statistically significant, suggesting that PearlMatrix may soon be seen as the gold standard for spinal graft materials used in TLIF procedures.

How Does PearlMatrix Fit Into the Broader Medical Device Landscape?

PearlMatrix’s FDA approval comes at a time of growing demand for clinically validated orthopedic devices. The U.S. sees approximately 465,000 spinal fusion procedures annually, according to industry estimates. The prevalence of high-risk patients has also increased, driven by rising obesity rates and an aging population. This demographic shift places further pressure on healthcare providers to adopt solutions with higher efficacy and faster recovery times.

In response to this challenge, medical device manufacturers have been racing to develop biologically active materials that improve upon existing graft solutions. Cerapedics’ success with PearlMatrix could signal a new direction for the industry—one in which evidence-based innovation takes precedence over volume-driven product development.

While many devices are cleared via the FDA’s 510(k) pathway, which allows quicker market access based on substantial equivalence, PMA-approved products must undergo years of clinical trials and data review. PearlMatrix’s entry into the market under this framework reinforces Cerapedics’ long-term credibility and may position the company as an acquisition target or IPO candidate in the near future.

What Are the Next Steps for Cerapedics and PearlMatrix?

Cerapedics confirmed that the complete results of the ASPIRE study will be published in full in the coming months, which may further influence clinical adoption and payer decisions. The company also plans to initiate broader commercial rollout of PearlMatrix across U.S. surgical centers and academic institutions.

Marketing efforts will likely target orthopedic and neurosurgical specialists, with a focus on hospital systems and physician groups looking to improve patient outcomes and reduce recovery durations. As payers increasingly demand high-quality, cost-effective solutions, products like PearlMatrix that are supported by robust clinical data may receive preferential reimbursement status.

The company has not disclosed pricing information, but given its PMA status and the cost burden associated with revision surgeries, PearlMatrix may be positioned as a premium product offering economic and clinical value.

Are There Broader Impacts on the Orthopedics and Biotech Sectors?

PearlMatrix’s FDA approval is expected to have ripple effects across the orthopedic medical device industry. Publicly traded competitors such as Medtronic, Stryker, and NuVasive may now face intensified scrutiny regarding the clinical performance of their existing graft products. While these companies have extensive product lines, few have achieved the PMA designation, which may prompt new investments in high-quality trials or acquisitions of innovative smaller firms like Cerapedics.

From a regulatory standpoint, PearlMatrix also sets a new bar for the level of clinical evidence needed to enter or dominate the spinal biologics market. Analysts suggest that companies with FDA-cleared but not PMA-approved products may need to reevaluate their clinical strategies if they wish to remain competitive.

Additionally, investor interest in spinal technologies is likely to grow. Although Cerapedics remains privately held, this regulatory success significantly raises its valuation and appeal to both venture capitalists and strategic buyers. In the context of ongoing healthcare cost containment, payers may also begin demanding higher standards of proof—something that PMA products like PearlMatrix are well-positioned to meet.

As of June 23, 2025, PearlMatrix stands not just as an FDA-approved bone graft, but as a potential paradigm shift in the management of lumbar spinal fusion. With its combination of biological innovation and proven efficacy in high-risk populations, it may well define the next chapter in evidence-based spine care.